Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: Realizing its potential

Research output: Contribution to journal › Article

Cite this

@article{4aa31ce37a7c441e9127aff8fe0b43f5,

title = "Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: Realizing its potential",

keywords = "Buprenorphine, Implant, Medication-assisted treatment, Opioid, Opioid use disorder, Sustained-release",

author = "Sigmon, {Stacey C.} and George Bigelow",

year = "2016",

doi = "10.1111/add.13539",

language = "English (US)",

journal = "Addiction",

issn = "0965-2140",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence

T2 - Realizing its potential

AU - Sigmon, Stacey C.

AU - Bigelow, George

PY - 2016

Y1 - 2016

KW - Buprenorphine

KW - Implant

KW - Medication-assisted treatment

KW - Opioid

KW - Opioid use disorder

KW - Sustained-release

UR - http://www.scopus.com/inward/record.url?scp=84992096746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992096746&partnerID=8YFLogxK

U2 - 10.1111/add.13539

DO - 10.1111/add.13539

M3 - Article

C2 - 27561982

AN - SCOPUS:84992096746

JO - Addiction

JF - Addiction

SN - 0965-2140

ER -